bis(3-hydroxypropyl)carbonate | 58823-34-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: bis(3-hydroxypropyl)carbonate
• 英文别名: bisPDO carbonate；Bis(3-hydroxypropyl) carbonate
• CAS: 58823-34-0
• 化学式: C₇H₁₄O₅
• 分子量: 178.185
• InChiKey: ZZIMHTCATWFOCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1,3-丙二醇 、 alkaline earth salt of/the/ methylsulfuric acid 在 甲烷磺酸 、 1,5,7-三氮杂双环[4.4.0]癸-5-烯 作用下， 反应 2.5h， 以67%的产率得到bis(3-hydroxypropyl)carbonate
  参考文献：
  名称：

  From plastic waste to polymer electrolytes for batteries through chemical upcycling of polycarbonate

  摘要：

  在二元醇存在下进行BPA-PC的去聚合，可以使其回收成BPA单体和含碳酸酯二元醇，后者可以聚合成脂肪族PC，作为储能应用的有前途的电解质。

  DOI：

  10.1039/d0ta03374j

文献信息

• PROCESS FOR PREPARING CARBONATE AND DIOL PRODUCTS
  申请人：Zhang Xiankuan

  公开号：US20130225840A1

  公开（公告）日：2013-08-29

  A method of forming a cyclic carbonate product is carried out by reacting an alkylene oxide, such as ethylene oxide, with carbon dioxide in the presence of a metal organic framework (MOF) catalyst with less than 0.5 mol % of any potassium or quaternary ammonium salts present based on moles of alkylene oxide feed in a reaction zone under reaction conditions to form a cyclic carbonate product. The cyclic carbonate product may be optionally fed as a crude carbonate product that does not undergo any purification or separation, other than the optional removal of any portion of unreacted alkylene oxide, carbon dioxide, and light hydrocarbon gases, to a second reaction zone containing a transesterification catalyst along with an aliphatic monohydric alcohol. The cyclic carbonate product and monohydric alcohol are allowed to react under reaction conditions to form the dialkyl carbonate and diol products.

  一种形成环状碳酸酯产品的方法是在反应区域中，在反应条件下，通过将烷基氧化物（如环氧乙烷）与二氧化碳在存在金属有机框架（MOF）催化剂的情况下反应，基于烷基氧化物进料的摩尔数，存在少于0.5摩尔％的任何钾盐或季铵盐，形成环状碳酸酯产品。环状碳酸酯产品可以选择性地作为未经任何纯化或分离的粗碳酸酯产品进料，除了可选择地去除任何未反应的烷基氧化物、二氧化碳和轻烃气体的部分，进入含有酯交换催化剂和脂肪族一元醇的第二反应区域。环状碳酸酯产品和一元醇在反应条件下允许反应，形成二烷基碳酸酯和二醇产品。
• (cyanomethyl)pyridines useful as PAF antagonists
  申请人：J. URIACH & CIA. S.A.

  公开号：EP0441226A1

  公开（公告）日：1991-08-14

  57 The present invention relates to new (cyanomethyl)pyridines of general formula I: wherein A is nitrogen and B is -CH-, or B is nitrogen and A is -CH-; the group Y-W- represents a group of formula N-CR1(CN)-, N-CH2-CH(CN)-, CH-CH(CN)- or C=C(CN)- wherein R1 is hydrogen or a C1-C6 alkyl group; R represents a group of formula R2CO-, R3R4N-(CH2)nCO- or R5-(CH2)m wherein R2 represents C1-C15 alkyl, aryl, aryl-(C1-C6)-alkyl, aryl-(C1-C6)-alkenyl, diaryl-(C1-C6)-alkyl, diaryl-(C1-C6)-alkenyl, arylhydroxy-(C1-C6)-alkyl, diarylhydroxy-(Ci-C6)-alkyl, aryl-(C1-C6)-alkoxy, diaryl-(C1-C6)-alkoxy, or heteroaryl-(C1-C6)-alkyl group; n is 0, 1, 2 or 3; R3 is hydrogen, C1-C6 alkyl, aryl or aryl-(Cl-C6)-alkyl group; R4 is C3-C6 cycloalkyl, aryl, aryl-(C1-C6)-alkyl, diaryl-(C1-C6)-alkyl, aryl-(C1-C6)-alkylcarbonyl or diaryl-(C1-C6)-alkylcarbonyl group; m is 0, 1 or 2; and R5 is aryl-(C1-C6)-alkyl, diaryl-(C1-C6)-alkyl, diaryl-(C1-C6)-alkylcarbonylamino or diaryl-(C1-C6)-alkylaminocarbonyl group. These compounds are potent, orally active PAF antagonists and consequently, useful in the treatment of the diseases in which this substance is involved.

  本发明涉及一般式I的新(氰甲基)吡啶：其中A为氮，B为-CH-，或者B为氮，A为-CH-；基团Y-W-表示一种具有以下式N-CR1(CN)-、N-CH2-CH(CN)-、CH-CH(CN)-或C=C(CN)-的基团，其中R1为氢或C1-C6烷基；R表示一种具有以下式R2CO-、R3R4N-( )nCO-或R5-( )m的基团，其中R2表示C1-C15烷基、芳基、芳基-(C1-C6)-烷基、芳基-(C1-C6)-烯基、二芳基-(C1-C6)-烷基、二芳基-(C1-C6)-烯基、芳基羟基-(C1-C6)-烷基、二芳基羟基-(Ci-C6)-烷基、芳基-(C1-C6)-氧基、二芳基-(C1-C6)-氧基或杂芳基-(C1-C6)-烷基；n为0、1、2或3；R3为氢、C1-C6烷基、芳基或芳基-(Cl-C6)-烷基；R4为C3-C6环烷基、芳基、芳基-(C1-C6)-烷基、二芳基-(C1-C6)-烷基、芳基-(C1-C6)-烷基羰基或二芳基-(C1-C6)-烷基羰基；m为0、1或2；R5为芳基-(C1-C6)-烷基、二芳基-(C1-C6)-烷基、二芳基-(C1-C6)-烷基羰胺基或二芳基-(C1-C6)-烷基氨基羰基基团。这些化合物是有效的口服PAF拮抗剂，因此，在这种物质参与的疾病治疗中非常有用。
• Method for direct conversion of carbon dioxide to dialkyl carbonates using ethylene oxide as feedstock
  申请人：E3TEC SERVICE, LLC

  公开号：US10941105B1

  公开（公告）日：2021-03-09

  A method for co-production of high purity dimethyl carbonate and mono-ethylene glycol by applying a reactor, such as a membrane reactor and/or an adsorbent-catalytic reactor by capturing and reacting carbon dioxide with methanol and ethylene oxide. Carbon dioxide may be recovered from primary sources (utilities and industrial processes) by a membrane or solid adsorbent, and subsequently converted to an intermediate hydroxy-ethyl-methyl carbonate by reacting with ethylene oxide and methanol. For high-purity carbon dioxide (obtained by carbon capture technologies or from an ethanol fermentation process), the membrane reactor is replaced with a catalytic reactor for direct conversion of carbon dioxide to hydroxy-ethyl-methyl carbonate by reacting with ethylene oxide and methanol. The hydro-ethyl-methyl carbonate is further reacted with methanol for conversion to dimethyl carbonate. A combination of heterogeneous and homogeneous catalysts is implemented for an effective conversion of carbon dioxide. An integrated reactive distillation process using side reactors is used for facilitating catalytic reaction for production of high purity dimethyl carbonate.

  应用反应器（如膜反应器和/或吸附剂催化反应器）通过捕集和反应二氧化碳与甲醇和乙烯氧共同生产高纯度的碳酸二甲酯和单乙二醇的方法。二氧化碳可以从主要来源（公用事业和工业过程）通过膜或固体吸附剂回收，并随后通过与乙烯氧和甲醇反应将其转化为中间体羟乙基甲基碳酸酯。对于高纯度的二氧化碳（通过碳捕集技术或乙醇发酵过程获得），将膜反应器替换为催化反应器，直接将二氧化碳与乙烯氧和甲醇反应转化为羟乙基甲基碳酸酯。羟乙基甲基碳酸酯进一步与甲醇反应转化为碳酸二甲酯。采用异质和均相催化剂的组合实现二氧化碳的有效转化。使用侧反应器的集成反应精馏过程用于促进生产高纯度碳酸二甲酯的催化反应。
• Conveniently implantable sustained release drug compositions
  申请人：Wong G. Vernon

  公开号：US20060073182A1

  公开（公告）日：2006-04-06

  This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

  本发明提供了生物相容性和可生物降解的可注射液体、可植入固体和可注射凝胶制药配方，用于治疗系统性和局部疾病状态。
• A combination of beta-adrenoceptor antagonists and anxiolytic agents
  申请人：AYERST, MCKENNA AND HARRISON INC.

  公开号：EP0098113A1

  公开（公告）日：1984-01-11

  A β-adrenoceptor antagonist, which does not penetrate or penetrates poorly the brain, is combined with subther- apeutic doses of an anxiolytic agent, such as diazepam, to give a pharmaceutical composition, for treating anxiety, stress or aggressivity without deleterious side effects associated with the central nervous system.

  β-肾上腺素受体拮抗剂不渗透大脑或渗透性较差，与亚剂量的抗焦虑剂（如地西泮）结合使用可制成一种药物组合物，用于治疗焦虑、压力或攻击性，而不会产生与中枢神经系统有关的有害副作用。